Global Neurodegenerative Disorder Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Бесплатный пример отчета Бесплатный пример отчета Узнать перед покупкой Узнать перед покупкой Купить сейчас Купить сейчас

Global Neurodegenerative Disorder Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Medical Devices
  • Upcoming Report
  • Dec 2024
  • Global
  • 350 Pages
  • Количество таблиц: 220
  • Количество рисунков: 60

Обходите тарифные трудности с помощью гибкого консалтинга в области цепочки поставок

Анализ экосистемы цепочки поставок теперь является частью отчетов DBMR

Global Neurodegenerative Disorder Therapeutics Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Chart Image USD 17.30 Billion USD 26.89 Billion 2024 2032
Diagram Прогнозируемый период
2025 –2032
Diagram Размер рынка (базовый год)
USD 17.30 Billion
Diagram Размер рынка (прогнозируемый год)
USD 26.89 Billion
Diagram CAGR
%
Diagram Основные игроки рынка
  • Biogen
  • Merck Sharp & Dohme Corp
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Orion Corporation

Global Neurodegenerative Disorder Therapeutics Market Segmentation, By Indication (Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others), Drug Glass (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), Route of Administration (Oral, Injection, Transdermal), End- User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2032

Neurodegenerative Disorder Therapeutics Market

Neurodegenerative Disorder Therapeutics Market Analysis

World Population Prospects predicts that by 2050, there will be 2.1 billion individuals over the age of 60 and that the number of persons over the age of 80 would triple to 425 million. 5.8 million Americans currently have Alzheimer's disease, and by 2050, the figure is expected to reach 14 million, according to the Alzheimer's Association. The market is driven by the rising demand for treatments for neurodegenerative disorders as a result of the incidence of neurodegenerative illnesses among the ageing population.

Neurodegenerative Disorder Therapeutics Market Size

Global neurodegenerative disorder therapeutics market size was valued at USD 17.30 billion in 2024 and is projected to reach USD 26.89 billion by 2032, with a CAGR of 5.67% during the forecast period of 2025 to 2032.

Report Scope and Market Segmentation       

Attributes

Neurodegenerative Disorder Therapeutics Key Market Insights

Segmentation

  • By Indication: Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others
  • By Drug Glass: Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others
  • By Route of Administration: Oral, Injection, Transdermal
  • By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Key Market Players

Biogen (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Orion Corporation (Finland), UCB S.A. (Belgium), ACADIA Pharmaceuticals Inc. (U.S.), Mitsubishi Chemical Group Corporation (Japan), H. Lundbeck A/S (Denmark), Denali Therapeutics (U.S.), Aquinnah Pharmaceuticals (Japan), Prevail Therapeutics (U.S.), AZTherapies, Inc. (U.S.)

Market Opportunities

  • Improvement in the healthcare infrastructure
  • Development of novel therapies

Neurodegenerative Disorder Therapeutics Market Definition

A variety of fatal diseases known as "neurodegenerative disorders" predominantly affect the neurons in the human brain and cause the progressive degeneration or death of nerve cells. The field of therapeutics for neurodegenerative disorders focuses on the production and research of medications and treatments that halt or reduce the neurodegenerative processes of illnesses including Parkinson's, Alzheimer's, Huntington's, and other neurodegenerative disorders.

Neurodegenerative Disorder Therapeutics Market Dynamics

Drivers

  • Rise in prevalence of neurodegenerative diseases

Increased financing for neurodegenerative disease research is anticipated to boost market expansion. The market for neurodegenerative disorder therapeutics is expected to grow rapidly from 2025 to 2032 as a result of a number of additional factors, including an increase in the prevalence of neurodegenerative diseases, an ageing population, a rise in the risk of neurological disorders like Alzheimer's and Parkinson's disease, and a better understanding of the genetic foundations and molecular pathology of neurodegenerative diseases.

  • Increase in elderly population

The market for therapies for neurodegenerative disorders is expanding as the prevalence of these diseases among the world's population rises. The rise in the population of elderly people is attributed to the rise in neurodegenerative illnesses.

Opportunities

The development of novel therapies for neurodegenerative disorders through gene and cell therapies and the massive scope for adoption of neurodegenerative disorders therapeutics in emerging nations will act as opportunities for market growth.

Restraints/Challenges

On the other hand, increasing failure rate of neurodegenerative drugs in clinical trials will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.

This neurodegenerative disorder therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurodegenerative disorder therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Neurodegenerative Disorder Therapeutics Market Scope

The neurodegenerative disorder therapeutics market is segmented on the basis of indication, drug glass, route of administration and end- user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Multiple sclerosis
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Huntington’s Disease
  • Others

Drug Glass

  • Immunomodulator
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Others

 Route of Administration

  • Oral
  • Injection
  • Transdermal

 End- User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Neurodegenerative Disorder Therapeutics Market Regional Analysis

The neurodegenerative disorder therapeutics market is analyzed and market size insights and trends are provided by country, indication, drug glass, route of administration and end- user as referenced above.

The countries covered in the neurodegenerative disorder therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the neurodegenerative disorder therapeutics market due to increasing awareness about the neurodegenerative disorder in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2025 to 2032 due to the rising health awareness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Neurodegenerative Disorder Therapeutics Market Share

The neurodegenerative disorder therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neurodegenerative disorder therapeutics market.

Neurodegenerative Disorder Therapeutics Market Leaders Operating in the Market Are:

  • Biogen (U.S.)
  • Merck Sharp & Dohme Corp (U.S.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Orion Corporation (Finland)
  • UCB S.A. (Belgium)
  • ACADIA Pharmaceuticals Inc. (U.S.)
  • Mitsubishi Chemical Group Corporation (Japan)
  • H. Lundbeck A/S (Denmark)
  • Denali Therapeutics (U.S.)
  • Aquinnah Pharmaceuticals (Japan)
  • Prevail Therapeutics (U.S.)
  • AZTherapies, Inc. (U.S.)

Latest Developments in Neurodegenerative Disorder Therapeutics Market

  • In January 2020, Biogen Inc., an America Biotechnology company acquired a novel clinical stage asset, PF-05251749 along with the applications from Pfizer for USD 75 million


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

Рынок сегментирован на основе Segmentation, By Indication (Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others), Drug Glass (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), Route of Administration (Oral, Injection, Transdermal), End- User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2032 .
Размер Global Neurodegenerative Disorder Therapeutics Market в 2024 году оценивался в 17.30 USD Billion долларов США.
Ожидается, что Global Neurodegenerative Disorder Therapeutics Market будет расти со среднегодовым темпом роста (CAGR) 5.67% в течение прогнозируемого периода 2025–2032.
Основные участники рынка включают Biogen , Merck Sharp & Dohme Corp , Novartis AG , Teva Pharmaceutical Industries Ltd. , Orion Corporation , UCB S.A. , ACADIA Pharmaceuticals Inc. , Mitsubishi Chemical Group Corporation , H. Lundbeck A/S , Denali Therapeutics , Aquinnah Pharmaceuticals , Prevail Therapeutics , AZTherapiesInc. .
Отчет по рынку охватывает данные из U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Testimonial